Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

Non-Small-Cell Lung Carcinoma Clinical Trial

Official title:

A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00137800
• Other study ID #: 02-308
• Status: Completed
• Phase: Phase 2
• Start date: February 2003
• Est. completion date: March 2007

Study information

• Verified date: April 2020
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.

Description:

Patients will receive OSI-774 once daily without interruption. There are no pre-determined number of cycles or planned dose interruptions. For the purposes of evaluation, toxicity and efficacy, a four week (28 day period) will be considered 1 cycle.

Patients will continue to receive OSI-774 until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study.

Patients will have radiographic evaluations after every two cycles of therapy. After cycle 2, patients will also be evaluated by FDG-PET scanning.

Patients will also be asked to fill out a Lung Cancer Symptom Scale (LCSS) on the first day of each cycle.

Bloodwork will also be performed on day 1 of each cycle as well as at the end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: March 2007
• Est. primary completion date: May 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Age: 70 years of age or older

• Stage IV or IIIB non-small cell lung cancer (NSCLC)

• Measurable tumor(s)

• Three or more weeks since prior radiation therapy

• Three or more weeks since prior major surgery

• Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities.

• Must be up and about more than 50% of waking hours.

• Life expectancy of 8 weeks or more

• Blood tests that show kidneys, liver and bone marrow to be working adequately

• Completely healed from previous oncologic or other major surgery

Exclusion Criteria:

• Prior chemotherapy regimen for non-small cell lung cancer

• Prior exposure to OSI-774 or similar treatments such as trastuzumab, ZD1839, C225, etc.

• Uncontrolled central nervous system metastases

• Concurrent active cancer

• Malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin

• Prior chemotherapy for any malignant disease

• Difficulty swallowing

• A disease or disorder that interferes with ability to digest and absorb food

• A medical condition that could make it unsafe for patient to participate in this study

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small-Cell Lung Carcinoma

Intervention

Drug:
• OSI-774 (Tarceva)
Once daily without interruption as long as there is no disease progression or serious side effects experienced.

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Brigham and Women's Hospital, Genentech, Inc., Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (2)

Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15;22(16):3238-47. — View Citation

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine how well non-small cell lung cancer cells in the body respond to OSI-774		2 years
Primary	To determine the survival rate of patients treated with OSI-774
Secondary	To determine the safety of OSI-774 in people 70 years of age or older		2 years
Secondary	To see how OSI-774 affects overall quality of life		2 years

External Links

•   Dana-Farber Cancer Institute Lowe Thoracic Oncology Program